Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 183

Results For "NAL"

5575 News Found

Caplin Group commences operations of Rs. 150 crore oncology facility
News | March 28, 2024

Caplin Group commences operations of Rs. 150 crore oncology facility

The facility will manufacture tablets, capsules, and injections for the oncology segment


EC approves Merck’s Keytruda plus chemotherapy as neoadjuvant treatment for non-small cell lung cancer
Drug Approval | March 28, 2024

EC approves Merck’s Keytruda plus chemotherapy as neoadjuvant treatment for non-small cell lung cancer

Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results


Data privacy, security and ethical challenges must for adoption of GenAI in healthcare: PwC India
Digitisation | March 27, 2024

Data privacy, security and ethical challenges must for adoption of GenAI in healthcare: PwC India

The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement


Sanofi and Cipla enters into distribution partnership to expand reach of CNS portfolio in India
Supply Chain | March 27, 2024

Sanofi and Cipla enters into distribution partnership to expand reach of CNS portfolio in India

Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium


Apollo Cancer Centres heralds a new era in breast cancer surgery
Healthcare | March 27, 2024

Apollo Cancer Centres heralds a new era in breast cancer surgery

The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions


Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
Drug Approval | March 27, 2024

Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder

First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+


FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
Drug Approval | March 27, 2024

FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension

WINREVAIR is a breakthrough biologic for this rare, progressive disease


AstraZeneca Pharma India appoints Vinay Sharma as Business Unit Head - Rare Disease
People | March 26, 2024

AstraZeneca Pharma India appoints Vinay Sharma as Business Unit Head - Rare Disease

Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology